106 related articles for article (PubMed ID: 38743809)
1. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
[TBL] [Abstract][Full Text] [Related]
2. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
3. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
4. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
6. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
8. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA
Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344
[TBL] [Abstract][Full Text] [Related]
9. PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.
Tutuka CSA; Andrews MC; Mariadason JM; Ioannidis P; Hudson C; Cebon J; Behren A
Mol Cancer; 2017 Jun; 16(1):112. PubMed ID: 28659148
[TBL] [Abstract][Full Text] [Related]
10. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
Song Q; Sun X; Guo H; Yu Q
Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
[TBL] [Abstract][Full Text] [Related]
11. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
12. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
13. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
14. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF
Lee B; Sahoo A; Sawada J; Marchica J; Sahoo S; Layng FIAL; Finlay D; Mazar J; Joshi P; Komatsu M; Vuori K; de Jong PR; Ray A; Perera RJ
J Invest Dermatol; 2021 Feb; 141(2):385-394. PubMed ID: 32888955
[TBL] [Abstract][Full Text] [Related]
16. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
17. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.
Chen G; Gao C; Gao X; Zhang DH; Kuan SF; Burns TF; Hu J
Mol Cancer Ther; 2018 Apr; 17(4):806-813. PubMed ID: 29167314
[TBL] [Abstract][Full Text] [Related]
18. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
Dietrich P; Kuphal S; Spruss T; Hellerbrand C; Bosserhoff AK
Oncogene; 2018 Feb; 37(7):897-911. PubMed ID: 29059159
[TBL] [Abstract][Full Text] [Related]
19. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
20. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]